Objective: The safety and efficacy of noninitial rapid infusion(90 min infusion schedule) of rituximab plus chemotherapy were evaluated in Chinese patients with CD20 positive (CD20+)non-Hodgkins lymphoma (NHL).Methods: From September 2009 to April 2013, 314 patients with CD20+ NHL were enrolled in this prospective study, of which 177 patients received four to six cycles of rituximabbased chemotherapy.The median age of these 177 patients was 49.4 (16 to 79) years old, and 109 of them were male.The first cycle of each patient was given with standard schedule.